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ㅋ
That gastrointestinal motility can influence the gut microbiota has been known for decades and the clinical consequences of 
impaired motility, in terms of the bacterial population of the small intestine, amply illustrated by the syndrome of small in-
testinal bacterial overgrowth which so commonly accompanies diffuse intestinal motility disorders. As the importance of the 
microbiota to homeostasis in health and to a variety of disease states is increasingly appreciated and as the full diversity and 
biology of this “hidden organ” have been revealed by molecular methodologies, the true nature of the interaction between 
the microbiota and motility is being re-examined and the complexity of this relationship exposed. In health, as well as in dis-
ease states, this is a truly bi-directional relationship: not only can gut motor patterns influence the microbiota but changes 
in the microbiota can exert profound influences on gut sensori-motor function.
(J Neurogastroenterol Motil 2011;17:140-147)
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Introduction
The gut microbiota (formerly referred to as the gut flora) and 
its interactions, both symbiotic and pathogenic, with the host, have 
become one of the hottest areas in biomedical science.
1 This ex-
plosion in research and knowledge has its origins in both the lab-
oratory and the clinic. While, in the laboratory, the application of 
modern molecular techniques, such as genomics and metab-
olomics, has revealed the true size, genetic diversity and metabolic 
complexity of the bacterial components of the microbiota,
2,3 clin-
ical observations have highlighted the importance of the micro-
biota and host-microbe interactions in health and disease.
1,4 It is 
now acknowledged that the number of bacteria within the gut is 
about 10 times that of all of the cells in the human body, that the 
microbiome contains much more genetic material than the host 
and that it represents a formidable metabolic “organ,” not only 
being capable of extracting calories from food components im-
penetrable to the host but also elaborating a large array of bio-
logically important compounds ranging from short-chain fatty 
acids and gases to antibiotics and neuro-modulatory substances. 
Techniques based on 16S rRNA sequences have revealed that the 
diversity of the human microbiota is much greater than pre-
viously thought and that the majority of bacterial sequences cor-
respond to unculturable sequences and novel bacteria.
3
Motility-Microbiota Interactions: The Basics
The Development of the Microbiota
Interactions between the microbiota and motility may be evi-
dent from the earliest stages of life. The developmental aspects of Microbiota and Motility
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the microbiota are also of clinical interest, given the importance of 
early life events to the pathophysiology of disorders such as irrita-
ble bowel syndrome (IBS). At birth, the entire intestinal tract is 
sterile; bacteria enter the gut with the first feed.
5 Following in-
fancy, the composition of the intestinal microbiota remains rela-
tively constant thereafter. Motor patterns, motor responses and 
enteric neuromuscular physiology also evolve over this time 
period.
6-8 That the phenomena of motor and microbiota matura-
tion are related is most vividly illustrated by studies in germ-free 
animals
9; not only are motor patterns disrupted in these animals 
but enteric neural and muscular function and morphology are 
abnormal. When disturbed, the microbiota has a remarkable ca-
pacity to restore itself and to return to exactly the same state as it 
was before.
1 Whether this restorative capacity is equally evident 
in the neonate and infant remains to be defined; it is possible that 
disturbances to the microbiota at this formative stage in its evolu-
tion may have more permanent consequences. It has recently 
been suggested, for example, that antibiotic use in early child-
hood is a significant risk factor for the development of in-
flammatory bowel disease in later life.
10
Motor Patterns and the Microbiota
Relationships between motility and the microbiota are evi-
dent in the normal intestine. Indeed, it is because of the presence 
of such normal motility patterns as peristalsis and the migrating 
motor complex, acting together with the antimicrobial effects of 
gastric acid, that the stomach and proximal small intestine contain 
relatively small numbers of bacteria in healthy subjects; jejunal 
cultures may not detect any bacteria in as many as 33%.
11,12 The 
relationship between the integrity of the migrating motor com-
plex and the absence of small intestinal bacterial overgrowth 
(SIBO) was, in fact, first described in man almost 35 years ago by 
Vantrappen et al.
13 The microbiology of the terminal ileum repre-
sents a transition zone between the jejunum containing predom-
inantly facultative anaerobes and the dense population of anae-
robes found in the colon. Bacterial colony counts may be as high 
as 1 × 10
9 CFU/mL in the terminal ileum immediately proximal 
to the ileocecal valve, with a predominance of Gram-negative or-
ganisms and anaerobes. On crossing into the colon, the bacterial 
concentration and variety of the enteric microbiota change 
dramatically. Specialized motor patterns of the terminal ileum
14,15 
(where the migrating motor complex is less evident in man
15), as 
well as the physiological and bio-mechanical properties of the 
ileo-colonic junction,
16,17 no doubt contribute to these ileo-co-
lonic bacterial gradients. Concentrations as high as 1 × 10
12 
CFU/mL may be found in the colon; comprised mainly of anae-
robes such as Bacteroides, Porphyromonas, Bifidobacterium, Lacto-
bacillus and Clostridium, with anaerobic bacteria outnumbering 
aerobic bacteria by a factor of 100-1,000:1.
4 The predominance 
of anaerobes in the colon reflects the fact that oxygen concen-
trations in the colon are very low; the microbiota has simply 
adapted to survive in this hostile environment!
Luminal Versus Mucosal Microbiota
At any given level of the gut, the composition of the micro-
biota also demonstrates variation along its diameter with certain 
bacteria tending to be adherent to the mucosal surface while oth-
ers predominate in the lumen
18; studies which rely on the analysis 
of the fecal microbiota alone may miss the impact of an important 
population of organisms: those closely adherent to the mucosa.
3 
Indeed, there is considerable interest in the potential role of these 
juxta-mucosal organisms in the initiation and/or perpetuation of 
inflammation in inflammatory bowel disease.
19,20 Motility, in-
cluding the contractile activity of both the longitudinal and circu-
lar muscle layers could well be seen to play a role in determining 
the relative numbers and diversity of bacteria in the center and at 
the periphery of the lumen. 
“Normal” Variations in the Microbiota
In humans, the composition of the microbiota is also influ-
enced by age, diet and socio-economic conditions and, above all, 
by the use of antibiotics; factors that may also influence motor 
patterns. Whether these changes in the microbiota and motility 
are related or independent events remains to be defined. There is 
a suggestion that SIBO occurring in the elderly in the absence of 
any other identifiable cause may be consequent upon age-related 
changes in small intestinal motility.
21 Given these “normal” varia-
tions in the microbiota, studies purporting to identify alterations 
in the microbiota in disease states must, accordingly, be in-
terpreted with great care and some degree of skepticism. 
Motility and the Microbiota; Who Is in Charge?
Motility and the microbiota are clearly associated; the ques-
tion is which is calling the tune? The conventional doctrine is that 
motor patterns influence the size, location and diversity of the mi-
crobiota; thus the clinical association between a variety of motor 
disorders and SIBO. That the microbiota can influence motor 
patterns has been vividly illustrated, not only by the afore-
mentioned studies in the germ-free animal, but also in ex-
perimental models of the short bowel syndrome where resection Eamonn M M Quigley
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of extensive portions of normal, more distal small intestine result 
in profound motor disruption in the more proximal remnant.
22 
These dramatic motor changes occur in the context of a dramatic 
increase in the bacterial population, as well as the concentration of 
a bacterial product, short chain fatty acids, in the remnant.
23-25
These observations make teleological sense: motility seeks to 
rid the gut of a presence that it senses to be pathogenic. Extensive 
studies in a murine model of enteric nematode infestation have 
revealed, in great detail, the physiological, morphological and ul-
trastructrual changes that can result from transient infestation 
and that appear to be mediated via the immune response; the net 
effect being the expulsion of the invader.
26
Barbara et al,
9 in their elegant review, identified 3 mecha-
nisms whereby the microbiota could influence gut motor func-
tion: (1) through the release of bacterial substances or end-prod-
ucts of bacterial fermentation, (2) via intestinal neuroendocrine 
factors
27 and (3) indirectly through the effects of mediators re-
leased by the gut immune response.
A variety of bacterial components and products have been 
shown to affect motility.
9 Indeed, the potential for short-chain 
fatty acids and another bacterial metabolite, deconjugated bile 
salts, to generate potent motor responses has been amply demon-
strated in both animal models
28,29 and man.
30,31 The bile salt ef-
fects may well be relevant to bile salt diarrhea, a phenomenon that 
has recently enjoyed a renaissance as a factor in the etiology of di-
arrhea-predominant IBS
32 and has even led to the exploration of 
bile salts as a therapeutic intervention for constipation-predom-
inant IBS.
33 In other studies, modifications in the microbiota in-
duced by dietary changes have been shown to alter motor patterns 
in the duodenum and jejunum.
34 The fermentation of un-
absorbed carbohydrates is a function of the colonic microbiota; 
quantitative changes in gas volume could be seen to elicit reflex 
responses induced by distension whereas qualitative changes, 
such as an overproduction of methane, have been shown to di-
rectly inhibit motor activity.
35 Abnormal gas handling has been 
identified as a factor in the pathogenesis of bloating and dis-
tension in irritable bowel syndrome
36; how the microbiota con-
tributes to this phenomenon is unknown. That a modification of 
the microbiota can lead to changes in colonic fermentation in man 
has been amply demonstrated in studies which, either by employ-
ing a prebiotic which selectively increased the numbers of bifido-
bacteria
37 or by directly supplementing bifidobacteria,
38 reduced 
colonic fermentation. Changes in fermentation influence motor 
function, not just in the colon, but at sites as distant as the lower 
esophageal sphincter
39 and stomach.
40
While microbial effects on gut mucosal neuroendocrine 
function have been recognized for some time,
27 it has only been 
recently that the ability of components of the microbiota to elabo-
rate molecules that have the potential to influence gut motor and 
sensory function has been recognized. Certain species have been 
shown to elaborate neurotransmitter peptides, as well as the in-
hibitory neurotransmitter gas, nitric oxide.
41 Perturbation of the 
flora by an antibiotic has been shown to increase substance P im-
munoreactivity and induce hypersensitivity in the colon
42; in con-
trast, certain commensal strains have the capacity to modulate in-
testinal pain through the induction of opioid and cannabinoid 
receptors.
43
The microbiota and the host enjoy many complex inter-
actions which include influences on the gut epithelium and its in-
tegrity, the mucosal and systemic immune systems and the gut- 
brain axis. Each of these areas has been the subject of extensive 
research; suffice it to say that effects of the microbiota on the mu-
cosal barrier, immune responses and neuroendocrine responses 
could have direct and indirect impacts on the function and, even, 
the morphology of gut muscle and nerve. Such studies have illus-
trated relationships between mucosal inflammation and gut mo-
tor and sensory functions,
44 the ability of modifications of the mi-
crobiota to influence gut barrier function
45-47 and the con-
sequences to the host of deficits in the latter.
48 Given the current 
focus on the possible contributions of inflammation to motor dys-
function in a variety of dysmotility and functional disorders, these 
microbe-immune responses have attracted considerable attention.
Motility-Microbiota Interactions: Clinical
Implications
While the list of gastrointestinal and non-gastrointestinal dis-
orders that may be related to some disturbance in the microbiota 
and/or the microbiota-host interaction is lengthy, I will illustrate 
the bidirectionality of this relationship, so evident in laboratory 
studies, with 2 clinical entities: SIBO and IBS.
Small Intestinal Bacterial Overgrowth
Although SIBO is usually defined in quantitative terms, as 
the number of colony forming units per mL, the interpretation of 
such definitions must be mindful, firstly, of the location, in the in-
testine, from where the sample was obtained and, secondly, of the 
fact that the majority of bacterial species in the gut remain 
unculturable. Alternatively, the diagnosis may be based on the 
presence of such consequences of SIBO as malabsorption, com-Microbiota and Motility
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bined with a positive result from such noninvasive diagnostic 
methods as breath tests. These reservations notwithstanding, 
SIBO is usually, and pending the validation of a more accurate 
methodology based on molecular microbiology, defined as the 
presence of > 1 × 10
5 CFU per mL of bacteria in the proximal 
small bowel.
49
Dysmotility predisposes to an increase in colonic bacteria in 
the small intestine; diseases resulting in impaired intestinal mo-
tility are, therefore, likely to have SIBO as a complication. Sclero-
derma and diabetic gastroenteropathy are among the more com-
mon disorders that exemplify the occurrence of SIBO in the con-
text of impaired motility; indeed, SIBO may complicate any of 
the many conditions that lead to the syndrome of chronic in-
testinal pseudo-obstruction. Reflecting the predilection of small 
intestinal myopathic disorders to SIBO, this complication has 
been documented in 43%-56% of patients with scleroderma.
50,51 
The prevalence of SIBO was higher among those with a higher 
global symptom score and, especially, among those with a high 
score for digestive symptoms. Other risk factors for SIBO in-
cluded the presence of diarrhea and constipation. Eradication of 
SIBO, successful in 52%-73%, resulted in symptom improve-
ment.
50,51 SIBO is associated with small intestinal diverticulosis. 
Diverticula in the jejunum occur in 0.07% to 2% of the pop-
ulation, are twice as frequent in men and are observed predom-
inantly among those over 60 years of age. Morphological studies 
suggest that disorders of intestinal motility such as progressive 
systemic sclerosis, visceral myopathies and neuropathies play an 
important role in the formation of the small bowel diverticula.
52 
However, by far the greatest controversy related to SIBO 
over the past decade and a half has been the proposal that SIBO is 
linked to IBS. The initial reports from Pimentel et al,
53,54 using 
the lactulose breath test, documented SIBO in 84% of their pa-
tients with IBS. Normalization of the lactulose breath test in this 
group, by use of neomycin, resulted in a significant improvement 
in IBS symptoms. Furthermore, methane excretion, on breath 
testing, was highly associated with a constipation-predominant 
subgroup of IBS. The same group found that their IBS patients 
with SIBO exhibited both a lower number and duration of phase 
III of the MMC, on antroduodenal manometry, in comparison 
to control subjects. Significant concerns have been raised regard-
ing the validity of this association.
55-59 In an important systematic 
review and meta-analysis of the link between SIBO and IBS, 
Ford et al
60 drew attention to the impact of test modality on SIBO 
prevalence, the average prevalence of SIBO on breath tests being 
54%; in sharp contrast to a mean prevalence of just 4% for jejunal 
aspirate cultures.
60 These authors also drew attention to the im-
pact of diagnostic criteria, which varied considerably between 
studies, on study outcome.
60 To muddy the waters further it has 
been suggested that the apparent link between SIBO and IBS 
may represent the impact of the proton pump inhibitors which are 
prescribed so readily in this patient population.
61 My personal 
opinion is that, while some patients with SIBO may present with 
IBS-type symptoms, SIBO is not a major contributor to the 
pathogenesis of IBS, in general. Furthermore, I believe that the 
modest improvement in IBS symptoms that has now been re-
ported with some consistency in IBS with antibiotic therapy may 
owe more to the effects of these agents on the colonic flora rather 
than SIBO.
62-64 This is supported both by the presence, in the 
study by Sharara et al,
65 of a symptomatic response to antibiotic 
therapy among subjects with a normal baseline breath test and by 
the very recent demonstration that accelerated small bowel trans-
it, and not SIBO, was the major contributor to positive lactulose 
breath tests in IBS.
66 These and other considerations have led to a 
serious re-evaluation of the status of SIBO in IBS.
67
Irritable Bowel Syndrome
Approximately 10%-20% of adults in the West have symp-
toms consistent with IBS. A combination of visceral hyper-
sensitivity, smooth muscle spasm and impairment of central pain 
processing likely contribute to the pain associated with IBS, while 
altered intestinal motility underlies the disordered defecation ex-
perienced by some patients with IBS.
Over the decades, various theories have been advanced to ex-
plain the pathogenesis of symptoms in the IBS patient, including 
dysmotility, visceral hypersensitivity and the psyche. The concept 
of the gut brain axis, emphasizing the interactivity at sensory, mo-
tor and neuro-endocrine levels, between the brain and the gut has 
provided a useful paradigm to encompass these diverse factors. 
This axis has been extended, by some, to include interaction be-
tween the gut flora (or microbiota), the immune system (both 
mucosal and systemic), the gut and the brain (the gut-brain-im-
mune-microbial axis). In this scenario, interactions between the 
flora (be it normal and disturbed) and the mucosal immune sys-
tem (gut-, or mucosa-associated lymphoid tissue) lead to the re-
lease of peptides and other neuro-active substances which gen-
erate, both locally and systemically, the neuro-muscular events 
that typify IBS and generate the patient’s symptoms. One of the 
most convincing pieces of evidence supporting the involvement 
of the microbiota in IBS is the phenomenon of post-infectious 
IBS. We are now beginning to see real data to directly support Eamonn M M Quigley
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the concept of post-infectious IBS. The occurrence of IBS fol-
lowing episodes of bacteriologically-confirmed gastroenteritis has 
now been documented in several studies. Thabane et al
68 con-
cluded that the overall risk for the development of IBS was in-
creased 6-fold following an episode of bacterial gastro-enteritis 
with younger subjects, those who have prolonged fever during 
the episode of gastroenteritis and those who suffer from anxiety 
or depression being at greatest risk.
Post-infectious IBS may explain only a minority of cases of 
IBS but it does illustrate a clear link between exposure to an envi-
ronmental agent, inflammation and IBS in predisposed indivi-
duals. Thus, Gwee et al
69 demonstrated an increase in the num-
ber of chronic inflammatory cells in the rectal mucosa among 
those patients exposed to bacterial gastroenteritis who had devel-
oped IBS. Others have demonstrated a persisting increase in rec-
tal mucosal enteroendocrine cells, T lymphocytes and gut perme-
ability in patients with post-dysenteric IBS.
70,71 These observa-
tions are important as they indicate a relationship between pertur-
bations of the microbiota, mucosal inflammation and IBS, an hy-
pothesis that is amply supported by data from studies in ex-
perimental animal models. In IBS, in general, evidence for a role 
for the microbiota can also be inferred from observations suggest-
ing the presence of immune activation and subtle levels of in-
flammation in IBS. Such evidence was first provided by Cha-
dwick et al
72  who demonstrated microscopic inflammation or im-
mune activation in among diarrhea-predominant IBS. Subse-
quent studies have provided further evidence of T lympho-
cyte
73,74 and mast cell activation
75-78 in the mucosa in IBS; others 
have demonstrated an extension of inflammation into the myo- 
neural compartments
79 and others still cytokine profiles in pe-
ripheral blood mononuclear cells
80,81 and serum
82 compatible with 
a pro-inflammatory state. 
It is attractive to suggest that these immunological changes 
could result from exposure to an exogenous (such as bacterial) 
antigen challenge.
83,84 That IBS patients may be predisposed to 
an, albeit contained, inflammatory response to luminal triggers is, 
indeed, supported by the finding of polymorphisms in genes that 
encode for the production of anti-inflammatory cytokines among 
IBS patients
85,86 and by the very recent description of high titers 
of anti-flagellin antibodies in serum derived from IBS patients.
87,88 
Further, more direct, support for this hypothesis comes from the 
demonstration of elevated levels of defensins in fecal fluid
89 and 
of upregulation of Toll-like receptor 4
90 in IBS.
So is there direct evidence for changes in the microbiota in 
IBS? While, in the past, various studies had suggested the pres-
ence of qualitative changes in the colonic flora in IBS patients; a 
relative decrease in the population of bifidobacteria being the 
most consistent finding.
91,92 Several factors limit the interpret-
ability of these studies, including the unrepresentative nature of 
the fecal flora, a failure to describe those bacterial populations 
that may be adherent to the mucosal surface and, above all, the 
recognition that a very significant proportion of the colonic mi-
crobiota cannot be identified by conventional culture methods. 
Molecular methods are now being applied to this complex issue 
and have, indeed, confirmed that IBS patients, regardless of 
sub-type, do exhibit a fecal flora that is clearly different from con-
trol subjects.
18,93-95 The precise nature of these differences and 
their potential to disturb mucosal or myoneural function, in the 
gut wall, or induce local or systemic immune responses, remains 
to be defined. 
Conclusion
In the past, the relationship between motility and the micro-
biota was viewed as unidirectional with motility maintaining the 
sterility of the upper gastrointestinal tract and dysmotility predis-
posing to small intestinal bacterial overgrowth. This narrow con-
cept has been cast aside with the recognition of the ability of the 
microbiota to influence the development of normal motor pat-
terns and the potential for disturbances in the microbiota to elicit 
motor responses or, if sustained, to lead to sensori-motor dys-
function and motility and, perhaps, functional disorders such as 
IBS. Accordingly, therapeutic approaches which modify the mi-
crobiota, including prebiotics, probiotics and antibiotics are being 
explored in IBS.
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